# Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)

> **NCT02253745** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vernalis (R&D) Ltd** · enrollment: 31 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** V81444
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02253745
- **Lead sponsor:** Vernalis (R&D) Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-03
- **Final completion:** 2014-04
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2016-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02253745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02253745, "Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02253745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*